Literature DB >> 19267957

Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats.

Jennifer François1, Arielle Ferrandon, Estelle Koning, Marie-José Angst, Guy Sandner, Astrid Nehlig.   

Abstract

Post-mortem studies suggested a disturbance of the GABAergic system in schizophrenia. Neonatal ventral hippocampal-lesioned (NVHL) rats were used as a neurodevelopmental model of schizophrenia. Here, we characterized the GABAergic system, focusing on the GABA-synthesizing enzyme, GAD67, GABAergic interneuron characteristic proteins, and the GABA transporter, gat-1. As the GABAergic system is crucial to brain excitability, the sensitivity to pentylenetetrazol (PTZ) administration, an antagonist of GABAA receptors, was also evaluated in such rats. Male pups were lesioned with ibotenic acid at postnatal day 7. As adults, they were submitted to standard behavioural tests, i.e. prepulse inhibition of the startle reflex and increased locomotion under apomorphine, to assess the effectiveness of the lesions and the PTZ infusion test before immunohistochemistry of the GABAergic neuron markers. We found a widespread perturbation of the enzyme responsible for GABA synthesis, GAD67 and a decrease of specific interneurons, restricted to the hippocampus, entorhinal and prefrontal cortex, but no alteration of gat-1-positive fibres. The usual behavioural properties of the model, such as hyperlocomotion under apomorphine and a deficit in sensorimotor gating were confirmed. NVHL rats showed changes in cortical excitability reflected by higher susceptibility than sham-operated rats to spike wave discharges and decreased susceptibility to clonic seizures, induced by increasing the dose of PTZ. These findings indicate that a neonatal lesion of the ventral hippocampus elicits alterations in the GABAergic system leading to functional consequences on brain excitability, lending support to the idea that GABAergic systems could be involved in the pathophysiology of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19267957     DOI: 10.1017/S1461145709009985

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  34 in total

1.  Transient inactivation of the neonatal ventral hippocampus permanently disrupts the mesolimbic regulation of prefrontal cholinergic transmission: implications for schizophrenia.

Authors:  Julie M Brooks; Martin Sarter; John P Bruno
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 2.  Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia.

Authors:  Michael J Gandal; J Christopher Edgar; Kerstin Klook; Steven J Siegel
Journal:  Neuropharmacology       Date:  2011-02-22       Impact factor: 5.250

3.  Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia.

Authors:  Stephanie M Perez; David D Aguilar; Jennifer L Neary; Melanie A Carless; Andrea Giuffrida; Daniel J Lodge
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

Review 4.  Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Authors:  Bernat Kocsis; Ritchie E Brown; Robert W McCarley; Mihaly Hajos
Journal:  CNS Neurosci Ther       Date:  2013-04-24       Impact factor: 5.243

5.  Nonsteroidal anti-inflammatory treatment prevents delayed effects of early life stress in rats.

Authors:  Heather C Brenhouse; Susan L Andersen
Journal:  Biol Psychiatry       Date:  2011-06-16       Impact factor: 13.382

6.  Neonatal hippocampal lesions in rhesus macaques alter the monitoring, but not maintenance, of information in working memory.

Authors:  Eric Heuer; Jocelyne Bachevalier
Journal:  Behav Neurosci       Date:  2011-09-19       Impact factor: 1.912

7.  Hyper-response to Novelty Increases c-Fos Expression in the Hippocampus and Prefrontal Cortex in a Rat Model of Schizophrenia.

Authors:  Tomas Monfil; Rubén Antonio Vázquez Roque; Israel Camacho-Abrego; Hiram Tendilla-Beltran; Tommaso Iannitti; Ivan Meneses-Morales; Patricia Aguilar-Alonso; Gonzalo Flores; Julio Cesar Morales-Medina
Journal:  Neurochem Res       Date:  2017-12-06       Impact factor: 3.996

8.  An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.

Authors:  Li Chen; Stephanie M Perez; Daniel J Lodge
Journal:  Dev Neurobiol       Date:  2014-03-03       Impact factor: 3.964

Review 9.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

Review 10.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.